Getinge has been affected since the first week of April when the USA's first tariffs were introduced. Medical technology has traditionally been exempt from trade tariffs, but in this case with the USA, there are no exceptions.
A dialogue is ongoing between us as an industry and the new administration in the USA regarding this, and I know that the EU's negotiators have it on their agenda as well. But right now, we can't do much else than follow the development and continue, says Mattias Perjos to TT.
Adapting
He says that the starting point now is that the tariffs will remain in some form and that the company must try to adapt to it.
Both through price increases and cost savings, and maybe in the long run, rethink some things in the supply chain as well.
Mattias Perjos also warns of more long-term consequences of the USA's trade tariffs.
First and foremost, this is really a cost increase issue that in the long run will affect patients and taxpayers, unfortunately. And furthermore, it risks distorting competition and making it so that innovation doesn't benefit patients in the way it would have otherwise.
Better Operating Profit
Getinge made a profit before tax of 428 million kronor for the first quarter. This can be compared to the profit of 638 million the same period last year.
The adjusted operating profit, however, increased, from 784 million to 896 million kronor. This was significantly better than the adjusted profit of 770 million kronor that the stock analysts had counted on, according to Bloomberg's prognosis compilation.
The turnover increased from 7.5 billion kronor to 8.3 billion. The order intake simultaneously increased from 8.1 billion to 8.6 billion kronor.
The share fell on Tuesday by nearly five percent on the Stockholm Stock Exchange.
